AI-optimized monoclonal antibody GB-0669 was safe and well-tolerated in healthy adults with dose-proportional pharmacokinetics and a 54-day half-life and dose-dependent serum live virus neutralization.
Source article: Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix
The Journal of Infectious DiseasesHow should this claim be treated?
ace